ACBD3: A Potential Drug Target and Biomarker for Parkinson's Disease

Target Name: ACBD3

NCBI ID: G64746

ACBD3

ACBD3: A Potential Drug Target and Biomarker for Parkinson's Disease

Parkinson's disease is a neurodegenerative disorder characterized by the progressive loss of brain cells, leading to motor symptoms such as tremors, rigidity, and difficulty with movement. The most common cause of Parkinson's disease is the neurotransmitter dopamine, which is deficient in the affected cells. The protein ACBD3 has been identified as a potential drug target and biomarker for Parkinson's disease. This article will discuss theACBD3 protein, its function, and its potential as a drug target in the treatment of Parkinson's disease.

ACBD3: The Undiscovered Double-Stranded Protein

ACBD3 is a protein that was first identified in the brain by researchers using a technique called co-expression gene expression. The protein is synthesized in the brain and has been shown to be expressed in the dopamine-producing neurons, which are the most affected cells in Parkinson's disease. The protein is also co-expressed with the protein PKA (RIalpha)-associated protein (PAPP), which is a protein that is known to interact with PKA and regulate the levels of dopamine in the brain.

The Double-Stranded Structure of ACBD3

The ACBD3 protein has a double-stranded structure, which is composed of two distinct regions: the N-terminal region and the C-terminal region. The N-terminal region is the first 110 amino acids of the protein and is responsible for its transmembrane structure. The C-terminal region is the last 29 amino acids of the protein and is involved in the formation of a disulfide bond.

The ACBD3 protein has a unique feature that is not found in other proteins, which is a double-stranded loop in the C-terminal region. This loop is composed of the amino acids Asp-20, Asp-21, Asp-22, Asp-23, Asp-24, Asp-25, Asp-26, Asp-27, Asp-28, Asp-29, Asp-30, Asp-31, Asp-32, Asp-33, Asp-34, Asp-35, Asp-36, Asp-37, Asp-38, Asp-39, Asp-40, Asp-41, Asp-42, Asp-43, Asp-44, Asp-45, Asp-46, Asp-47, Asp-48, Asp-49, Asp-50, Asp-51, Asp-52, Asp-53, Asp-54, Asp-55, Asp-56, Asp-57, Asp-58, Asp-59, Asp-60, Asp-61, Asp-62, Asp-63, Asp-64, Asp-65, Asp-66, Asp-67, Asp-68, Asp-69, Asp-70, Asp-71, Asp-72, Asp-73, Asp-74, Asp-75, Asp-76, Asp-77, Asp-78, Asp-79, Asp-80, Asp-81, Asp-82, Asp-83, Asp-84, Asp-85, Asp-86, Asp-87, Asp-88, Asp-89, Asp-90, Asp-91, Asp-92, Asp-93, Asp-94, Asp-95, Asp-96, Asp-97, Asp-98, Asp-99, Asp-100, and Asp-101.

The ACBD3 protein has a unique function in the brain, which is to regulate the levels of dopamine in the brain. Studies have shown that ACBD3 is involved in the production and degradation of dopamine, as well as the regulation of the levels of dopamine transporter (DAT) in the brain.

Potential as a Drug Target

The lack of effective treatments for Parkinson's disease has led to the search for new drug targets. The ACBD3 protein is a potential drug target, as it is involved in the production and regulation of dopamine in the brain. By targeting ACBD3, researchers may be able to develop new treatments for Parkinson's disease.

One approach to targeting ACBD3 is to use small molecules, such as drugs that can modulate the activity of ACBD3. These drugs could be used to treat symptoms of Parkinson's disease, such as tremors and rigidity. Another approach is to use antibodies that can target ACBD3 and prevent it from interacting with PKA and DAT. This could lead to a reduction in the levels of dopamine in the brain, which could potentially slow the progression of Parkinson's disease.

Biomarker

ACBD3 may also be used as a biomarker for Parkinson's disease. The ACBD3 protein is expressed in the brain and has been shown to be involved in the production and regulation of dopamine in the brain. By measuring the levels of ACBD3 in the brain, researchers may be able to monitor the progression of Parkinson's disease and the effectiveness of new treatments.

Conclusion

ACBD3 is a protein that has been identified as a potential drug target and biomarker for Parkinson's disease. Its unique double-stranded structure and involvement in the production and regulation of dopamine in the brain make it an attractive target for researchers. Further studies are needed to determine the effectiveness of ACBD3 as a drug and to understand its potential as a biomarker for Parkinson's disease.

Protein Name: Acyl-CoA Binding Domain Containing 3

Functions: Involved in the maintenance of Golgi structure by interacting with giantin, affecting protein transport between the endoplasmic reticulum and Golgi (PubMed:11590181). Involved in hormone-induced steroid biosynthesis in testicular Leydig cells (By similarity). Recruits PI4KB to the Golgi apparatus membrane; enhances the enzyme activity of PI4KB activity via its membrane recruitment thereby increasing the local concentration of the substrate in the vicinity of the kinase (PubMed:27009356)

The "ACBD3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ACBD3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets